The global acute
myeloid leukemia therapeutics market is expected to witness notable growth, in
the coming year due to increase in the new innovative and targeted drug delivery
system. Various factors such as rising awareness regarding cancer treatments,
increasing demand for safe and successful medications, rising incidence of
cancer and technological advancements have been driving the growth of the
global acute myeloid leukemia therapeutics market. Apart from this, various
regulatory bodies are supporting the growth of the global market with funding,
designations and grants, thereby accelerating the drug development process.
According to National Cancer Institute,
a part of the U.S. National Institutes of Health, acute myeloid leukemia is a
type of cancer that affects the blood and bone marrow. Acute myeloid leukemia
is characterized by overproduction of immature white blood cells, myeloblasts
or leukemic blasts. These cells crowd the bone marrow, preventing it from
making normal blood cells. They can also spill out into the blood stream and
circulate around the body. Due to their immaturity, these cells are unable to
prevent or fight infections.
Download
Report Sample at:
The pipeline of acute myeloid leukemia
contains Durvalumab, a Phase II drug candidate of MedImmune. It is a fully
human monoclonal antibody, which helps to overcome the immunosuppressive
effects of B7-H1 on T-cells. Takeda Pharmaceutical Company Limited is
developing a Phase II drug candidate, Alisertib, for the treatment of acute
myeloid leukemia. It is an orally active, small-molecule inhibitor of the
aurora A kinase. The aurora family of protein kinases is involved in the
regulation of cell growth and proliferation, particularly in chromosome segregation
and cytokinesis.
Make
Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=acute-myeloid-leukemia-therapeutics-market
The acute myeloid leukemia therapeutics market was
the largest market in the U.S. region of North America in year 2016, and it is
expected to remain the largest during the forecast period due to large number
of research and development activities.
Some of the key players operating in
the acute myeloid leukemia therapeutics market include Celgene Corporation,
Eisai Co. Ltd., Bristol-Myers Squibb, Novartis AG, F. Hoffman La Roche AG,
Genmab A/S, GlaxoSmithKline plc, and Takeda Pharmaceutical Company Limited.
About P&S Intelligence
P&S Intelligence, a brand of P&S
Market Research, is a provider of market research and consulting services
catering to the market information needs of burgeoning industries across the
world. Providing the plinth of market intelligence, P&S as an enterprising
research and consulting company, believes in providing thorough landscape
analyses on the ever-changing market scenario, to empower companies to make informed
decisions and base their business strategies with astuteness.
Contact:
P&S Intelligence
Toll-free: +1-888-778-7886
(USA/Canada)
International: +1-347-960-6455
Email: enquiry@psmarketresearch.com
No comments:
Post a Comment